share_log

Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer

Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer

默克公司的Keytruda Combo试验未能达到治疗肝癌的主要目标
Benzinga Real-time News ·  2022/09/12 06:48
  • Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESALY) presented final analysis results from Phase 3 LEAP-002 of Keytruda plus Lenvima versus Lenvima as a first-line treatment for unresectable hepatocellular carcinoma (uHCC).
  • In the final analysis of the trial, there was a trend toward improvement for one of the study's dual primary endpoints, overall survival (OS); however, the results did not meet statistical significance.
  • Related: Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal.
  • The median OS was 21.2 months for Keytruda plus Lenvima and 19.0 months for Lenvima monotherapy.
  • Additionally, Keytruda plus Lenvima resulted in a trend toward improvement in progression-free survival (PFS) versus Lenvima monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance.
  • Price Action: MRK shares closed lower by 0.09% at $87.34 on Friday.
  • 默沙东(纽约证券交易所股票代码：MRK)和卫材株式会社(场外交易代码：ESALY)公布了Keytruda Plus Lenvima与Lenvima作为不能切除的肝细胞癌(UHCC)一线治疗方案的3期LEAP-002的最终分析结果。
  • 在试验的最终分析中，研究的双重主要终点之一--总体存活率(OS)有改善的趋势；然而，结果并不符合统计学意义。
  • 相关： 默克公司的两项Keytruda Combo癌症试验未能达到预期的主要目标.
  • Keytruda加Lenvima的中位OS为21.2个月，Lenvima单一治疗的中位OS为19.0个月。
  • 此外，Keytruda加Lenvima疗法与Lenvima单一疗法相比，在无进展存活率(PFS)方面有改善的趋势；然而，在第一次中期分析中，结果没有达到预先指定的阈值，具有统计学意义。
  • 价格行动：周五，Mr K股价收盘下跌0.09%，至87.34美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发